Highly increased risk of fracture in patients with myeloproliferative neoplasm

References

• Kanis JA, Odén A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239–2256.
   PubMed Web of Science ®Google Scholar
• Oden A, Kanis JA, McCloskey EV, et al. The effect of latitude on the risk and seasonal variation in hip fracture in Sweden. J Bone Miner Res. 2014;29(10):2217–2223.
   PubMed Web of Science ®Google Scholar
• Svedbom A, Borgstöm F, Hernlund E, et al. Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int. 2018;29(3):557–566.
   PubMed Web of Science ®Google Scholar
• Katsoulis M, Benetou V, Karapetyan T, et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med. 2017;281(3):300–310.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, et al. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev. 2016;30(6):453–459.
   PubMed Web of Science ®Google Scholar
• Abdulkarim K, Samuelsson J, Johansson P, et al. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: real-world data from the Swedish MPN Registry. Eur J Haematol. 2017;98(6):577–583.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Kristinsson SY, Andersson TM-L, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Cin Oncol. 2012;30(24):2995–3001.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132–1136.
   PubMed Web of Science ®Google Scholar
• Abdulkarim K, Girodon F, Johansson P, et al. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol. 2009;82(2):106–111.
   PubMed Web of Science ®Google Scholar
• Bjorkholm M, et al. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best Pract Res Clin Haematol. 2014;27(2):141–153.
   PubMed Web of Science ®Google Scholar
• Hoglund M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122(7):1284–1292.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130(23):2475–2483.
   PubMed Web of Science ®Google Scholar
• Landtblom AR, Bower H, Andersson TM-L, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32(10):2203–2210.
   PubMed Web of Science ®Google Scholar
• Andersen M, Sajid Z, Pedersen RK, et al. Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. PLoS One. 2017;12(8):e0183620.
   PubMed Web of Science ®Google Scholar
• Farmer S, Horváth-Puhó E, Vestergaard H, et al. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol. 2013;163(5):603–610.
   PubMed Web of Science ®Google Scholar
• Steer K, Stavnichuk M, Morris M, et al. Bone health in patients with hematopoietic disorders of bone marrow origin: systematic review and meta- analysis. J Bone Miner Res. 2017;32(4):731–742.
   PubMed Web of Science ®Google Scholar
• Valderrabano RJ, Wu JY. Bone and blood interactions in human health and disease. Bone. 2019;119:65–70.
   PubMed Web of Science ®Google Scholar
• Farmer S, Shanbhogue VV, Hansen S, et al. Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. Osteoporos Int. 2017;28(2):677–685.
   PubMed Web of Science ®Google Scholar
• Albertsson-Wikland K, Mårtensson A, Sävendahl L, et al. Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab. 2016;101(5):2149–2159.
   PubMed Web of Science ®Google Scholar
• Breslow NE, Day NE. Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. Lyon, France: IARC Scientific Publication; 1987.
   Google Scholar
• Johansson P, Lind Kristjansdottir H, Johansson H, et al. Increased risk of hip fracture in patients with lymphoma, a Swedish Population Study of 37,236 lymphoma patients. Calcif Tissue Int. 2020;106(6):591–598.
   PubMed Web of Science ®Google Scholar
• Jönsson S, Standal T, Olsson B, et al. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. Am J Hematol. 2012;87(5):550–552.
   PubMed Web of Science ®Google Scholar
• O'Sullivan S, Horne A, Wattie D, et al. Bone metabolism during long-term treatment with imatinib. Leuk Lymphoma. 2013;54(8):1783–1785.
   PubMed Web of Science ®Google Scholar
• O'Sullivan S, Naot D, Callon KE, et al. Imatinib mesylate does not increase bone volume in vivo. Calcif Tissue Int. 2011;88(1):16–22.
   PubMed Web of Science ®Google Scholar
• Hansen L, Judge A, Javaid MK, et al. Social inequality and fractures-secular trends in the Danish population: a case-control study. Osteoporos Int. 2018;29(10):2243–2250.
   PubMed Web of Science ®Google Scholar
• Benetou V, Orfanos P, Feskanich D, et al. Education, marital status, and risk of hip fractures in older men and women: the CHANCES project. Osteoporos Int. 2015;26(6):1733–1746.
   PubMed Web of Science ®Google Scholar
• Barker AL, Soh S-E, Sanders KM, et al. Aspirin and fracture risk: a systematic review and exploratory meta-analysis of observational studies. BMJ Open. 2020;10(2):e026876.
   PubMed Web of Science ®Google Scholar
• Kosaryan M, et al. The bone density of thalassemic patients of Boo Ali Sina Hospital, Sari, Iran in 2002 does hydroxyurea help? Pediatr Endocrinol Rev. 2004;2(Suppl 2):303–306.
   PubMedGoogle Scholar
• Baldini M, Marcon A, Ulivieri FM, et al. Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables. Ann Hematol. 2017;96(6):995–1003.
   PubMed Web of Science ®Google Scholar
• Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–846.
   PubMed Web of Science ®Google Scholar
• Eggold JT, Rankin EB. Erythropoiesis, EPO, macrophages, and bone. Bone. 2019;119:36–41.
   PubMed Web of Science ®Google Scholar
• Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood. 2005;105(7):2631–2639.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63–74.
   PubMed Web of Science ®Google Scholar
• Wu C, Giaccia AJ, Rankin EB, et al. Osteoblasts: a novel source of erythropoietin. Curr Osteoporos Rep. 2014;12(4):428–432.
   PubMed Web of Science ®Google Scholar
• Panaroni C, Fulzele K, Saini V, et al. PTH signaling in osteoprogenitors is essential for B-lymphocyte differentiation and mobilization. J Bone Miner Res. 2015;30(12):2273–2286.
   PubMed Web of Science ®Google Scholar
• Wu JY, Purton LE, Rodda SJ, et al. Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways. Proc Natl Acad Sci USA. 2008;105(44):16976–16981.
   PubMed Web of Science ®Google Scholar
• Oikonomidou PR, Casu C, Yang Z, et al. Polycythemia is associated with bone loss and reduced osteoblast activity in mice. Osteoporos Int. 2016;27(4):1559–1568.
   PubMed Web of Science ®Google Scholar
• Kristjansdottir HL, Lewerin C, Lerner UH, et al. High plasma erythropoietin predicts incident fractures in elderly men with normal renal function: the MrOS Sweden cohort. J Bone Miner Res. 2020;35(2):298–305.
   PubMed Web of Science ®Google Scholar
• Hiram-Bab S, Neumann D, Gabet Y, et al. Erythropoietin in bone - controversies and consensus. Cytokine. 2017;89:155–159.
   PubMed Web of Science ®Google Scholar